Update re Acquisition of Uranium Projects, USA & Issue of Equity
Update re Acquisition of Uranium Projects, USA & Issue of Equity
Avacta Therapeutics Presents Preclinical and Translational Data from pre|CISION® Platform Candidates at 2025 AACR Annual Meeting FAP-EXd (AVA6103) demonstrates tumor growth inhibition and durable complete responses in multiple therapy-resistant preclinical
Acquisitions support U.S. domestic mineral sourcing and energy transition initiatives
Metals One (AIM: MET1), which is advancing critical minerals projects, is pleased to provide the following corporate and strategic updates.
The CBS team visited Nalunaq to learn about Greenland’s potential for raw materials. Amaroq CEO Eldur Ólafsson spoke with CBS about Greenland’s mineral potential, mining and infrastructure and how the
Metals One (AIM: MET1), which is advancing strategic minerals projects in Finland and Norway, is pleased to announce the appointment of Fairfax Partners Inc., a boutique investor relations firm, to enhance the Company’s
Further to the announcement of 31 January 2025, Metals One (AIM: MET1), which is advancing strategic minerals projects in Finland and Norway, is pleased to announce that all conditions in respect of the
Update re Acquisition of Finland Copper Projects & Directorate Changes
AVA6000 Phase 1b expansion cohorts enrolling with data targeted for later in 2025 AVA6103 IND-enabling studies underway with a Phase 1 trial anticipated to begin in the first quarter
Amaroq Minerals Ltd. (AIM, TSX-V, NASDAQ Iceland: AMRQ), an independent mining company with a substantial land package of gold and strategic mineral assets in Southern Greenland, is pleased to announce
Avacta Therapeutics Announces Presentations at 2025 AACR Annual Meeting
Hammaslahti Cu-Zn and Outokumpu Cu projects expand Nordic footprint with key metal in high demand